Roche's Vabysmo shows potential to treat eye disorder common in Asia
Fierce Pharma
NOVEMBER 21, 2024
Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of Roche's Vabysmo on Asian patients with polypoidal choroidal vasculopathy suggest that the injected treatment is effective. After 16 weeks, patients showed vision improvement which was equivalent to reading roughly one and a half more lines on an eye chart.
Let's personalize your content